MX2020014124A - Preparacion de aptameros. - Google Patents
Preparacion de aptameros.Info
- Publication number
- MX2020014124A MX2020014124A MX2020014124A MX2020014124A MX2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A
- Authority
- MX
- Mexico
- Prior art keywords
- aptamer
- preparation
- aptamer preparation
- fgf2
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
La presente invención proporciona una formulación de preparación capaz de mantener de manera estable la actividad de un aptámero, particularmente un aptámero para FGF2, durante un largo periodo, proporcionando así una preparación farmacéutica que contiene un aptámero, particularmente un aptámero de FGF2, como un ingrediente activo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018124390 | 2018-06-29 | ||
PCT/JP2019/025766 WO2020004607A1 (ja) | 2018-06-29 | 2019-06-28 | アプタマー製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020014124A true MX2020014124A (es) | 2021-05-31 |
Family
ID=68986754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020014124A MX2020014124A (es) | 2018-06-29 | 2019-06-28 | Preparacion de aptameros. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210269802A1 (es) |
EP (1) | EP3815715B1 (es) |
JP (1) | JP7340264B2 (es) |
KR (1) | KR20210025083A (es) |
CN (1) | CN112384246A (es) |
AU (1) | AU2019292134A1 (es) |
BR (1) | BR112020026634A2 (es) |
CA (1) | CA3105002A1 (es) |
IL (1) | IL279595A (es) |
MX (1) | MX2020014124A (es) |
SG (1) | SG11202012933QA (es) |
TW (1) | TWI845521B (es) |
WO (1) | WO2020004607A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021157681A1 (ja) | 2020-02-06 | 2021-08-12 | 株式会社リボミック | 網膜下高反射病巣または網膜下高反射病巣を伴う網膜疾患の治療剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
CN101317820B (zh) | 2007-04-19 | 2012-02-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 生物亲和性配体分子介导的靶向脂质体,其制 备及其应用 |
US20110027126A1 (en) * | 2008-03-26 | 2011-02-03 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method of long term storage of substrate-coupled beads |
US9052323B2 (en) | 2009-08-27 | 2015-06-09 | The University Of Kansas | Osmolyte mixture for protein stabilization |
JP5899550B2 (ja) | 2010-02-12 | 2016-04-06 | 株式会社リボミック | Fgf2に対するアプタマー及びその使用 |
WO2014116789A1 (en) * | 2013-01-25 | 2014-07-31 | Thymon, Llc | Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection |
WO2015147017A1 (ja) * | 2014-03-24 | 2015-10-01 | 株式会社リボミック | Fgf2に対するアプタマー及びその使用 |
EP3161138A4 (en) * | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
JP2018124390A (ja) | 2017-01-31 | 2018-08-09 | 株式会社沖データ | 画像形成装置及び定着制御方法 |
-
2019
- 2019-06-28 TW TW108122887A patent/TWI845521B/zh active
- 2019-06-28 SG SG11202012933QA patent/SG11202012933QA/en unknown
- 2019-06-28 JP JP2020527674A patent/JP7340264B2/ja active Active
- 2019-06-28 US US17/256,368 patent/US20210269802A1/en active Pending
- 2019-06-28 KR KR1020217002648A patent/KR20210025083A/ko unknown
- 2019-06-28 AU AU2019292134A patent/AU2019292134A1/en active Pending
- 2019-06-28 WO PCT/JP2019/025766 patent/WO2020004607A1/ja unknown
- 2019-06-28 EP EP19825285.0A patent/EP3815715B1/en active Active
- 2019-06-28 CA CA3105002A patent/CA3105002A1/en active Pending
- 2019-06-28 MX MX2020014124A patent/MX2020014124A/es unknown
- 2019-06-28 CN CN201980043745.7A patent/CN112384246A/zh active Pending
- 2019-06-28 BR BR112020026634-5A patent/BR112020026634A2/pt not_active Application Discontinuation
-
2020
- 2020-12-20 IL IL279595A patent/IL279595A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019292134A1 (en) | 2021-02-11 |
IL279595A (en) | 2021-03-01 |
WO2020004607A1 (ja) | 2020-01-02 |
TWI845521B (zh) | 2024-06-21 |
US20210269802A1 (en) | 2021-09-02 |
EP3815715B1 (en) | 2024-09-11 |
TW202012625A (zh) | 2020-04-01 |
KR20210025083A (ko) | 2021-03-08 |
EP3815715A1 (en) | 2021-05-05 |
CA3105002A1 (en) | 2020-01-02 |
JPWO2020004607A1 (ja) | 2021-07-15 |
JP7340264B2 (ja) | 2023-09-07 |
CN112384246A (zh) | 2021-02-19 |
EP3815715A4 (en) | 2022-03-16 |
SG11202012933QA (en) | 2021-01-28 |
BR112020026634A2 (pt) | 2021-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
MX2021009377A (es) | Formulaciones de espuma y aparatos para su suministro. | |
MY185500A (en) | Macrocylic pyridine derivatives | |
MX2016000794A (es) | Composiciones farmaceuticas de pancreatina de potencia alta. | |
MX363545B (es) | Derivados piridin-4-ilo. | |
MX2022002946A (es) | Inhibidores de cdk y su uso como productos farmaceuticos. | |
PH12017502376A1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
TW201613592A (en) | Glucose metabolism ameliorating agent | |
MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
EA201691741A1 (ru) | Фармацевтическая композиция | |
GEP20196977B (en) | Pharmaceutical formulations of vildagliptin | |
MX2020014124A (es) | Preparacion de aptameros. | |
AU2017370226A1 (en) | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof | |
PH12019501785A1 (en) | Intranasal composition comprising betahistine | |
MX2017011005A (es) | Formulaciones estimulantes de liberacion tripulsos. | |
WO2016030899A8 (en) | Methods of treating amyotrophic lateral scleroses | |
MX2020008129A (es) | Composicion farmaceutica que comprende un derivado acilado de un analogo de insulina humana y metodo de preparacion de la misma. | |
PH12019500024A1 (en) | Pharmaceutical compositions | |
MX2022001772A (es) | Formulaciones de isotretinoina y usos y metodos de las mismas. | |
IN2014DN10134A (es) | ||
MY195763A (en) | A Herbicidal Composition and Process Thereof | |
PH12020551547A1 (en) | Pharmaceutical preparation | |
WO2015126151A3 (ko) | 신곡 추출물을 포함하는 상처 치료용 조성물 | |
EA201690706A1 (ru) | Пенообразующий препарат и устройство для доставки |